DMP Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €36.45 |
| 52 Week High | €42.68 |
| 52 Week Low | €29.90 |
| Beta | 1.14 |
| 11 Month Change | 15.17% |
| 3 Month Change | 1.67% |
| 1 Year Change | -8.97% |
| 33 Year Change | -54.21% |
| 5 Year Change | -3.32% |
| Change since IPO | 30.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 15.5% | -5.0% | -1.3% |
| 1Y | -9.0% | -22.0% | 7.4% |
Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: DMP underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DMP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| DMP fundamental statistics | |
|---|---|
| Market cap | €2.02b |
| Earnings (TTM) | €90.59m |
| Revenue (TTM) | €1.17b |
22.3x
P/E Ratio1.7x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMP income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €439.61m |
| Gross Profit | €734.32m |
| Other Expenses | €643.74m |
| Earnings | €90.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 62.55% |
| Net Profit Margin | 7.72% |
| Debt/Equity Ratio | 174.1% |
How did DMP perform over the long term?
See historical performance and comparison